cours de bourse
14/08/2009 - 11:07:23|49.66 EUR 0.42 %
Stallergenes posts revenue growth of 3.5% in 2013 and increases its...
During its meeting held on March 5, 2014, the Board of Directors of...
STALLERGENES, biopharmaceutical company
Major player in its market, Stallergenes established sublingual immunotherapy and remains the world leader in this area. Since 2003, the company is committed to the Stalair® development program, creating a new therapeutic class that covers 80% of respiratory allergies.
Check out the new awareness campaign on house dust mite allergy